Menta Capital LLC purchased a new stake in shares of Odonate Therapeutics Inc (NASDAQ:ODT) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 13,314 shares of the company’s stock, valued at approximately $187,000.
Several other institutional investors also recently bought and sold shares of ODT. Federated Investors Inc. PA purchased a new position in shares of Odonate Therapeutics during the 3rd quarter valued at $68,000. Tower Research Capital LLC TRC grew its holdings in shares of Odonate Therapeutics by 222.8% during the 3rd quarter. Tower Research Capital LLC TRC now owns 5,288 shares of the company’s stock valued at $102,000 after acquiring an additional 3,650 shares in the last quarter. TD Asset Management Inc. grew its holdings in shares of Odonate Therapeutics by 60.8% during the 4th quarter. TD Asset Management Inc. now owns 17,962 shares of the company’s stock valued at $253,000 after acquiring an additional 6,793 shares in the last quarter. Northern Trust Corp boosted its holdings in Odonate Therapeutics by 11.1% in the fourth quarter. Northern Trust Corp now owns 91,550 shares of the company’s stock worth $1,289,000 after purchasing an additional 9,125 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in Odonate Therapeutics by 29.1% in the fourth quarter. Geode Capital Management LLC now owns 93,842 shares of the company’s stock worth $1,321,000 after purchasing an additional 21,168 shares in the last quarter. Institutional investors and hedge funds own 94.02% of the company’s stock.
A number of equities research analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Odonate Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, December 14th. Cowen reiterated a “buy” rating on shares of Odonate Therapeutics in a report on Friday, February 22nd.
Shares of NASDAQ:ODT opened at $21.13 on Friday. The firm has a market capitalization of $565.23 million, a P/E ratio of -5.80 and a beta of 0.94. Odonate Therapeutics Inc has a 1 year low of $11.54 and a 1 year high of $28.57.
Odonate Therapeutics (NASDAQ:ODT) last issued its earnings results on Friday, February 22nd. The company reported ($1.17) EPS for the quarter, missing the consensus estimate of ($1.07) by ($0.10). On average, analysts anticipate that Odonate Therapeutics Inc will post -4.56 EPS for the current fiscal year.
About Odonate Therapeutics
Odonate Therapeutics, Inc, a pharmaceutical company, develops therapeutics for the treatment of cancer. It focuses on the development of tesetaxel, an orally administered chemotherapy agent for patients with advanced or metastatic breast cancer (MBC). Odonate Therapeutics, Inc also conducting a Phase III study in MBC, which is known as CONTESSA.
Want to see what other hedge funds are holding ODT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Odonate Therapeutics Inc (NASDAQ:ODT).
Receive News & Ratings for Odonate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Odonate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.